Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      BridGene Biosciences to Present Three Posters at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

      BridGene Biosciences (PRNewsfoto/BridGene Biosciences)

      News provided by

      BridGene Biosciences

      Oct 23, 2025, 08:33 ET

      Share this article

      Share this article


      --Discovery of a Novel Covalent FGFR3 Inhibitor with Potent Anti-Cancer Activity

      --Discovery of a First-in-Class Covalent PAX8 Inhibitor Targeting the DNA-Binding Domain

      --Broad Application of IMTAC™ Chemoproteomics to Identify Covalent Ligandable Sites Across the Proteome

      SAN JOSE, Calif., Oct. 23, 2025 /PRNewswire/ -- BridGene Biosciences, Inc., a leader in the discovery of small molecule drugs for traditionally "hard-to-drug" targets, announced today that three abstracts have been accepted for presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, taking place October 22-26, 2025, in Boston, Massachusetts. The presentations showcase new discoveries from BridGene's proprietary IMTAC™ (Isobaric Mass Tagged Affinity Characterization) chemoproteomics platform, including the identification of a novel covalent FGFR3 inhibitor, a first-in-class PAX8 inhibitor, and data illustrating the breadth and precision of IMTAC™ in mapping covalent ligandable sites across the proteome.

      BridGene will present findings from its study titled "Discovery of a Highly Potent and Selective Covalent FGFR3 Inhibitor," which details the identification and preclinical evaluation of a selective FGFR3 inhibitor discovered using the company's IMTAC™ chemoproteomics platform. The compound demonstrated irreversible binding to a previously uncharacterized cysteine residue in FGFR3, resulting in sustained inhibition of FGFR3 phosphorylation and downstream ERK signaling. In cellular models harboring FGFR3 alterations, the inhibitor exhibited nanomolar potency and strong antiproliferative effects, while maintaining high selectivity over other FGFR family members. These data support the potential of covalent FGFR3 inhibition as a novel therapeutic strategy for FGFR3-driven cancers and further validate BridGene's chemoproteomic approach for uncovering druggable sites in challenging targets.

      BridGene will present findings from its study titled "IMTAC™: A Proteome-Wide Live-Cell Screening Platform for Discovering Covalent Binders to Diverse Targets Including GPCRs, Phosphatases, and More." The research showcases how BridGene's proprietary IMTAC™ platform integrates a highly diverse covalent small molecule library with advanced live-cell chemical proteomics and quantitative mass spectrometry to identify direct, on-target binding events under native cellular conditions. The platform enables proteome-wide selectivity profiling, minimizes false positives, and reveals transient, novel binding pockets that are undetectable in traditional assays.

      Using IMTAC™, BridGene identified covalent binders across multiple challenging target classes, including GPCRs, phosphatases, and kinases. In GPCR studies, BGP-1951 inhibited serotonin-induced calcium influx through 5-HT₂A while avoiding common CNS toxicity profiles, and BGP-2992 acted as a positive allosteric modulator of CXCR4 signaling with therapeutic potential in neuroinflammation. Among phosphatases, BGP-15341 inhibited ENPP1 enzymatic activity at nanomolar potency, and BGP-1900 selectively bound PTPN2, offering a path toward targeted degradation strategies. In kinase assays, BGP-21172 showed strong selectivity for CDK7, and two ADK binders—BGP-1892 and BGP-13486—demonstrated nanomolar activity in target engagement assays.

      BridGene will present findings from "Discovery of a Covalent Inhibitor Targeting PAX8-Driven Ovarian Cancer" highlighting the identification of BGP-31609, a covalent small molecule inhibitor discovered through the IMTAC™ platform. BGP-31609 binds irreversibly to a single cysteine residue within the DNA-binding domain of PAX8, disrupting transcriptional activity and reducing the expression of downstream oncogenic targets including FGF18 and CCNA2. In biochemical and cellular assays, the compound showed dose-dependent inhibition of DNA binding in EMSA and selective suppression of PAX8-driven luciferase activity with minimal off-target effects. Importantly, BGP-31609 inhibited proliferation of PAX8-high OVCAR3 ovarian cancer cells while sparing PAX8-negative A549 cells, demonstrating target selectivity. These results establish BGP-31609 as a validated covalent binder to an historically undruggable transcription factor and a promising lead for treating PAX8-dependent malignancies.

      "We're excited to share these new discoveries that further validate the strength and versatility of our IMTAC™ chemoproteomics platform," stated Ping Cao, Ph.D., CEO and co-founder of BridGene Biosciences. "The data we're presenting at AACR-NCI-EORTC illustrate how IMTAC™ can uncover previously hidden binding sites and enable the development of covalent inhibitors against some of the most challenging oncology targets. These findings reflect our commitment to expanding what's possible in small molecule drug discovery and to translating this science into meaningful therapies for patients."

      The three poster presentations will be available on the AACR-NCI-EORTC conference website following the sessions. BridGene's scientific team will be available to discuss the data and the continued advancement of the company's IMTAC™ platform in driving discovery of covalent small molecule drugs for previously undruggable targets.

      Abstract Title: 

      Discovery of a Highly Potent and Selective Covalent FGFR3 Inhibitor

      Session:

      Poster Session B

      Date and Time: 

      Friday, October 24, 12:30-4pm

      Location:

      Hynes Convention Center, Boston - Level 2, Exhibit Hall D


      Abstract Title: 

      IMTAC™: A Proteome-Wide Live-Cell Screening Platform for Discovering Covalent Binders to Diverse Targets Including GPCRs, Phosphatases, and More

      Session:

      Poster Session C

      Date and Time: 

      Saturday, October 25, 12:30-4pm

      Location:

      Hynes Convention Center, Boston - Level 2, Exhibit Hall D


      Abstract Title: 

      Discovery of a Covalent Inhibitor Targeting PAX8-Driven Ovarian Cancer

      Session:

      Poster Session B

      Date and Time: 

      Friday, October 24, 12:30-4pm

      Location:

      Hynes Convention Center, Boston - Level 2, Exhibit Hall D

      About BridGene Biosciences

      BridGene is a biotechnology company focused on discovering and developing innovative small molecules that drug traditionally undruggable targets, providing new paths to treat diseases. By using its proprietary chemoproteomic platform, IMTAC™, BridGene can screen small molecules against all proteins in live cells to discover drug candidates for high-value and previously undruggable targets. BridGene is advancing a diversified pipeline of first-in-class drugs for targets in multiple disease areas. For more information, visit https://bridgenebio.com/.

      Contact
      Tiberend Strategic Advisors, Inc.
      Jonathan Nugent (investors)
      205-566-3026
      [email protected]

      Eric Reiss (media)
      [email protected]

      SOURCE BridGene Biosciences

      Modal title

      Also from this source

      /C O R R E C T I O N -- BridGene Biosciences/

      /C O R R E C T I O N -- BridGene Biosciences/

      BridGene Biosciences, Inc., a leader in the discovery and development of small molecule drugs for traditionally "hard-to-drug" targets, today...

      BridGene Biosciences Appoints Nobel Laureate Bruce A. Beutler, M.D., to Scientific Advisory Board

      BridGene Biosciences Appoints Nobel Laureate Bruce A. Beutler, M.D., to Scientific Advisory Board

      BridGene Biosciences, Inc., a leader in the discovery of small-molecule drugs for traditionally "hard-to-drug" targets, announced today the...

      More Releases From This Source

      Explore

      Health Care & Hospitals

      Health Care & Hospitals

      Biotechnology

      Biotechnology

      Medical Pharmaceuticals

      Medical Pharmaceuticals

      Pharmaceuticals

      Pharmaceuticals

      News Releases in Similar Topics

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.